Our DNA makes us unique and is where our superpowers may be hidden. By diving into a database of around 2M sequenced exomes - the functional parts of DNA - ’s uncovering the hidden heroes that may spark the future of genetics-based medicine. #SpectacularScience
Follow
Click to Follow Regeneron
Regeneron
@Regeneron
Official channel for Regeneron. We turn science into medicine for people with serious diseases. View our terms of engagement here ow.ly/UMYS30iRqZ4
Regeneron’s Tweets
Our Q4 2022 earnings webcast begins this morning at 8:30 AM EST.
1
4
The European Commission approved our medicine as the first & only targeted treatment for eligible adults and adolescents with eosinophilic esophagitis, a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. CC:
1
17
The CHMP recommended our medicine for approval in infants and young children as young as 6 months with severe atopic dermatitis.
CC:
1
1
We’re excited to introduce the 2023 #RegeneronSTS finalists! These bright, young minds are channeling their curiosity and passion into research that explores solutions to some of the most complex, global issues.
5
26
We are honored to be highlighted by the World Economic Forum Global Parity Alliance as part of the Diversity, Equity, and Inclusion (#DEI) Lighthouse Programme 2023. Read more about this cross-industry group and our DEI strategy:
4
As we modernize clinical trials, #patientcentricity is at the heart. Hear from Bari Kowal, SVP, Head of Development Operations & Portfolio Management, on key areas of innovation and their impact on the future of clinical development in :
6
Congratulations to our Blazers, Regeneron Science Talent Search Scholars: Nathan Shan, Josh Wang, Celine Wu! 🎉🎉🎉 👏🏽
Quote Tweet
With @Society4Science, we congratulate the 2023 #RegeneronSTS scholars, whose extraordinary research projects earned them a spot among an outstanding 300 peers.
Learn more about how these young scientists are using the power of STEM to contribute to our society.
1
3
28
With , we congratulate the 2023 #RegeneronSTS scholars, whose extraordinary research projects earned them a spot among an outstanding 300 peers.
Learn more about how these young scientists are using the power of STEM to contribute to our society.
1
6
20
Announcing a new PD-1 supply agreement with to investigate potential combination therapy, which marks the 7th clinical supply agreement involving our PD-1 inhibitor in a year.
Quote Tweet
We’re pleased to announce a clinical supply agreement with @Regeneron, which supports evaluation of our SNS-101 antibody in combination with Regeneron’s anti-PD1 therapy: bit.ly/3ZeVMYg
2
12
#BREAKING: Japan’s Ministry of Health, Labor and Welfare (MHLW) approved our #immunotherapy to treat advanced or recurrent #cervicalcancer in patients whose disease progressed on or after chemotherapy.
1
2
28
The CHMP recommended the approval of our medicine for eligible adults and adolescents 12 years and older with eosinophilic esophagitis (EoE), a chronic, progressive disease of the esophagus driven by underlying type 2 inflammation. CC:
1
7
We’re proud that selected Regeneron as a recipient of the COVID-19 Patents for Humanity Award. This award honors the innovation of our scientists who led the discovery and development of our COVID-19 treatment. Read more here: bit.ly/3FrPxam
1
2
14
#Breaking Our medicine was approved by the European Commission for adults with moderate-to-severe prurigo nodularis, a chronic skin disease associated with extreme itch. Read more: CC: bit.ly/3htRB9Y
1
4
At #ASH22, we’re presenting positive Phase 2 results from our investigational #bispecific antibody in relapsed/refractory #follicularlymphoma.
2
5
During #ASH22, we’re sharing positive Phase 1/2 data on our investigational #bispecific antibody in relapsed/refractory advanced #myeloma.
3
7
1
7
6
4
We’re proud Regeneron has won the 2022 Community Partnership of the Year Award for our work with to sponsor the annual Science Talent Search. #ScripAwards
#RegeneronSTS
Together, we’re nurturing the next generation of scientists!
4
22
At #ESMOImmuno22, we’re presenting research and insights from our diverse immuno-oncology pipeline, with data from seven abstracts across lung, ovarian, and cervical cancer. New insights span investigational candidates, combinations, and tumor types.
6
The U.S. FDA accepted our application for Priority Review for our medicine being investigated in children aged 5 to 11 with #HoFH, an ultra-rare condition that results in dangerously high levels of LDL-C, or bad cholesterol.
Learn more: bit.ly/3VFmHda
3
7
Congratulations to all those who competed in the 2022 #SciFest National Final in Ireland! We can’t wait to see this year’s champion at #RegeneronISEF.
Quote Tweet
Congratulations to @SciFest4STEM winners Liam Waldron, Rachel Griffin & Luke O'Sullivan of @KillarneyCommu1: Group-Theoretic Approach to Pythagoras’ Theorem. In May they will represent Ireland @ Regeneron International Science and Engineering Fair (ISEF) in Texas, USA.
@KerryETB
Show this thread
read image description
ALT
1
4
#BREAKING: The European Commission approved our #immunotherapy as a treatment option for recurrent or metastatic #cervicalcancer in Europe.
3
22
We’re announcing a new collaboration with to develop next generation bispecific immunotherapeutics for the potential treatment of cancer. Read our press release to learn more.
2
21
We applaud Kerry’s tremendous contributions to Regeneron and her commitment to supporting rising women leaders.
3
Show this thread
Congratulations to Kerry Reinertsen, Senior Vice President of Strategic Alliances, on being recognized among Westchester’s Top Women in Business of 2022 by .
1
2
17
Show this thread
Congratulations to Dr. Lori Morton, Vice President of Research, on being named one of the 2022 Fiercest Women in Life Sciences by !
Beyond Lori’s important work in the lab, she is committed to advancing women in science and STEM education. bit.ly/3Eu0fhm
5
15
With in vivo CRISPR technology, the ability to cut and paste genetic code is at our fingertips as we work to tackle serious diseases right inside the body. #SpectacularScience
1
3
We ❤ scientists like who not only help advance our knowledge of the world but also give back to their communities through #STEM education. In collaboration with and , our partner Raven recently helped students with a biology experiment.
3
33
The CHMP recommended the approval of our medicine in the EU for adults with moderate-to-severe prurigo nodularis, a chronic inflammatory skin disease characterized by intense itch and painful skin lesions. CC:
2
6
Today is the final day to apply for #RegeneronSTS, so complete those applications by 8 p.m. tonight! My colleagues at and I can't wait to meet this next class of young innovators and learn all about their original research sciencetalentsearch.smapply.org
5
11
16
46
During this year’s Meeting we presented positive data from our pivotal #clinicaltrial in wet age-related macular degeneration (#wetAMD) and diabetic macular edema. #RetinaSociety2022
4
We’re excited to be sharing new research at #ASH22 from 17 abstracts. Our data spans multiple investigational candidates from our hematology and hematologic oncology pipelines.
2
2
Our Q3 2022 earnings webcast begins this morning at 8:30 AM EDT.
1
3
Our DNA may hold the story of our history, but it is also writing our future. By building a database of around 2M sequenced exomes, the scientists of use #AI and #MachineLearning to mine the genetic superpowers found deep within a person’s DNA. #SpectacularScience
2
5
Congratulations to the 2022 #PrixGalien USA Award winners and our scientists who helped make this possible.
Quote Tweet
2
7
Today, RGC's will present at #ASHG22 on her latest research helping identify a potential therapeutic target for endometriosis. Learn more about RGC’s latest genetic breakthroughs: bit.ly/3Frsgqv
Quote Tweet
Find out what has @MariaC_Su excited for her #ASHG22 plenary session. Catch it live tonight at 5:30 PM PT.
2
Congratulations to Chris Fenimore, our SVP, Head of Accounting and Controller, who received a 2022 C-Suite Award.
Chris’s strategic mindset & dedication to collaboration have helped shape Regeneron since he joined in 2003! bit.ly/3figV1w
2